DESIGN OF NEW POTENTIAL 5-LIPOXYGENASE INHIBITORS, DUAL THROMBOXANE SYNTHASE INHIBITORS, AND THROMBOXANE A(2) RECEPTOR ANTAGONISTS BY AM1

被引:0
作者
ALBUQUERQUE, MG [1 ]
RODRIGUES, CR [1 ]
DEALENCASTRO, RB [1 ]
BARREIRO, EJ [1 ]
机构
[1] FED UNIV RIO DE JANEIRO,FAC FARM,DEPT TECNOL PHARMACEUT,AVALIACAO & SINTESE SUBST BIOAT LAB,BR-21944910 RIO JANEIRO,BRAZIL
关键词
D O I
暂无
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Leukotrienes and thromboxane A(2) are autacoids derived from arachidonic acid (5,8,11,14-icosatretraenoic acid). They are synthesized in cells by 5-lipoxygenase and thromboxane synthase, respectively. Leukotrienes are related to inflammatory and allergic diseases, while thromboxane A(2) is a potent platelet aggregating and vasoconstrictor agent involved in cardiovascular pathologies. In this article we have calculated partial potential energy surfaces at the AM1 level for some 5-lipoxygenase inhibitors,thromboxane synthase inhibitors, thromboxane A(2) receptor antagonists, and a dual blocker which inhibits thromboxane synthase and antagonizes thromboxane A(2) receptor. Our objective was to identify stereoelectronic properties and topographical requirements for these compounds that could be related to their biological activities. Based on our results and on molecular mechanisms of pharmacological action, we were able to propose new potential 5-lipoxygenase inhibitors and dual blockers derived from pyrazole, pyrrole, 1,2,3-triazole, and 1,2,4-triazole. (C) 1995 John Wiley & Sons, Inc.
引用
收藏
页码:181 / 190
页数:10
相关论文
共 50 条
[21]   SPECTRAL STUDIES ON STRUCTURE-ACTIVITY-RELATIONSHIPS OF THROMBOXANE SYNTHASE INHIBITORS [J].
HECKER, M ;
HAURAND, M ;
ULLRICH, V ;
TERAO, S .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 157 (01) :217-223
[22]   MODEL FOR THE STRUCTURE OF BACTERIORHODOPSIN BASED ON HIGH-RESOLUTION ELECTRON CRYOMICROSCOPY [J].
HENDERSON, R ;
BALDWIN, JM ;
CESKA, TA ;
ZEMLIN, F ;
BECKMANN, E ;
DOWNING, KH .
JOURNAL OF MOLECULAR BIOLOGY, 1990, 213 (04) :899-929
[23]   NEW APPROACH TO ANTI-INFLAMMATORY DRUGS [J].
HIGGS, GA ;
FLOWER, RJ ;
VANE, JR .
BIOCHEMICAL PHARMACOLOGY, 1979, 28 (12) :1959-1961
[24]   CLONING AND EXPRESSION OF CDNA FOR A HUMAN THROMBOXANE-A2 RECEPTOR [J].
HIRATA, M ;
HAYASHI, Y ;
USHIKUBI, F ;
YOKOTA, Y ;
KAGEYAMA, R ;
NAKANISHI, S ;
NARUMIYA, S .
NATURE, 1991, 349 (6310) :617-620
[25]   HIGHLY SELECTIVE INHIBITORS OF THROMBOXANE SYNTHETASE .1. IMIDAZOLE DERIVATIVES [J].
IIZUKA, K ;
AKAHANE, K ;
MOMOSE, DI ;
NAKAZAWA, M ;
TANOUCHI, T ;
KAWAMURA, M ;
OHYAMA, I ;
KAJIWARA, I ;
IGUCHI, Y ;
OKADA, T ;
TANIGUCHI, K ;
MIYAMOTO, T ;
HAYASHI, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1981, 24 (10) :1139-1148
[26]  
JAKUBOWSKI JA, 1992, ANNU REP MED CHEM, V27, P99
[27]   A PROPOSED COMMON SPATIAL PHARMACOPHORE AND THE CORRESPONDING ACTIVE CONFORMATIONS OF SOME TXA2 RECEPTOR ANTAGONISTS [J].
JIN, B ;
HOPFINGER, AJ .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1994, 34 (04) :1014-1021
[28]   THROMBOXANE SYNTHETASE INHIBITORS (TXSI) - DESIGN, SYNTHESIS, AND EVALUATION OF A NOVEL SERIES OF OMEGA-PYRIDYLALKENOIC ACIDS [J].
KATO, K ;
OHKAWA, S ;
TERAO, S ;
TERASHITA, Z ;
NISHIKAWA, K .
JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (03) :287-294
[29]  
KREUTNER W, 1984, ANNU REP MED CHEM, V19, P241
[30]  
KUBINYI H, 1993, QSAR HANSH ANAL RELA, P240